- Patients suffering from AMD and DR often require anti-vascular endothelial growth factor (anti-VEGF) agent injections into the eye
- Multiple injections are uncomfortable and difficult for patients to comply to
- Ocular and systemic safety of repeated injections unclear
- More than 10,000 injections per year are performed at the Singapore National Eye Centre (SNEC)
- 66 million people are affected by AMD, increasing at a rate of 1.85% annually from 2013
- Treatment market across US, UK, Germany, France, Spain, Italy and Japan will almost double in value from $5.1 billion in 2013 to $10.1 billion by 2023.
- SERID simultaneously injects therapeutic agents into the eye and extracts vitreous samples for biomarker analysis in a single puncture
- The device comprises an injection port, a vacuum port, and at least one needle for selective fluid communication between the injection and vacuum port.
- The device removes vitrous sample first to minimize a spike in the intraocular pressure, then the drug is administered in the same injection.
- The injection mechanism is currently an adapted 1mL syringe
- Preliminary ex vivo studies with porcine eyes has shown the mechanism and advantages of SERID.
Current IP Position: National Phase under examination (PCT/SG2016/050119 filed on 15 March 2016)
Seeking further funding opportunities into the start-up and/or collaboration to further enhance the existing system.
Dr Marcus Ang / SingHealth